Eisai Gains Access to Forma's Drug Screening Technology
November 18, 2010
Eisai Gains Access to Forma's Drug Screening Technology
In return for access to Forma's compound library and cell-based screening platforms, Eisai will pay $20 million upfront and in committed funding over three years, plus potential milestone and royalty payments.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.